175696-50-1

Basic information

• Product Name: N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine
• Synonyms: N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine
• CAS NO: 175696-50-1
• Molecular Formula: C₂₃H₄₇NO₅
• Molecular Weight: 417.62298
• Product Categories: Amines, Chiral Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 175696-50-1.mol
• Article Data: 33

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Dichloromethane
• CAS DataBase Reference: N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine(CAS DataBase Reference)
• NIST Chemistry Reference: N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine(175696-50-1)
• EPA Substance Registry System: N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine(175696-50-1)

Safety Data

• Hazardous Substances Data: 175696-50-1(Hazardous Substances Data)

Usage

Description

N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine is a synthetic compound derived from D-ribo-phytosphingosine, a naturally occurring sphingosine. It is characterized by its white solid appearance and is known for its antifungal properties.

Uses

Used in Pharmaceutical Industry:
N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine is used as an antifungal agent for its ability to inhibit the growth of various fungi. Its application in the pharmaceutical industry is primarily focused on the development of antifungal medications to treat fungal infections.
Used in Agricultural Industry:
In the agricultural industry, N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine is used as a biopesticide to protect crops from fungal infections. Its antifungal properties help in reducing the incidence of crop diseases caused by fungi, thereby improving crop yield and quality.
Used in Cosmetics Industry:
N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine is also utilized in the cosmetics industry as an ingredient in antifungal and antimicrobial products. Its incorporation in skincare and personal care products helps in maintaining hygiene and preventing fungal infections, especially in areas prone to moisture and warmth.
Used in Research and Development:
Due to its unique chemical properties and antifungal activity, N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine is employed in research and development for the discovery of new antifungal drugs and therapies. It serves as a valuable compound for studying the mechanisms of action against various fungal pathogens and for the development of novel treatment strategies.

Upstream product

• 3144-09-0 methanesulfonamide 
• 214556-61-3 (2R,3Z)-2-(tert-butoxycarbonyl)amino-3-octadecen-1-ol 
• 122709-20-0 N-(tert-butoxycarbonyl)-L-serine N'-methoxy-N'-methylamide 
• 122709-21-1 (4S)-2,2-Dimethyl-4-(N-methoxy-N-methylcarbamoyl)oxazolidin-3-carbonsaeure-(tert-butyl)ester 
• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 629-72-1 pentadecyl bromide 
• 1429195-22-1 C₂₇H₅₁NO₇ 
• 1332640-34-2 (R)-1-{(4R,5S)-5-[(S)-1-(benzylamino)allyl]-2,2-dimethyl-1,3-dioxolan-4-yl}-2-(tert-butyldimethylsilyloxy)ethanol 
• 1332640-41-1 (2S,3S,4r,Z)-2-(benzylamino)octadec-5-ene-1,3,4-triol 
• 1332640-40-0 (S)-3-benzyl-4-((4S,5R)-2,2-dimethyl-5-((Z)-tetradec-1-enyl)-1,3-dioxolan-4-yl)oxa-zolidin-2-one 
• 1332640-38-6 (S)-3-benzyl-4-((4S,5R)-5-((R)-1,2-dihydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-oxazolidin-2-one 
• 1332640-37-5 3-benzyl-4-((4S,5R)-5-((R)-2-(tert-butyldimethylsilyloxy)-1-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)oxazolidin-2-one 
• 1332640-36-4 benzyl benzyl((S)-1-((4S,5R)-5-((R)-2-(tert-butyldimethylsilyloxy)-1-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-hydroxyethyl)carbamate 
• 1332640-35-3 benzyl benzyl((S)-1-((4S,5R)-5-((R)-2-(tert-butyldimethylsilyloxy)-1-hydroxyethyl)-2,2-dimethyl-1,3-dioxolan-4-yl)allyl)carbamate 

Downstream Products

• 554-62-1 D-ribo-phytosphingosine 
• 799268-03-4 [(E)-(S)-1-((4S,5R)-2,2-Dimethyl-5-tetradecyl-[1,3]dioxolan-4-yl)-3-((2R,3S,4R,5S,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-allyl]-carbamic acid tert-butyl ester 
• 116467-63-1 N-tert-butyloxycarbonylsphingosine 
• 1089188-04-4 (2S,3S,4R)-1-O-(6-deoxy-6-phenylaminocarbonylamino-α-D-galactopyranosyl)-2-[(N-hexacosanoyl)amino]octadecane-3,4-diol 
• 898531-99-2 (2S,3S,4R)-1-O-(6-deoxy-6-acetamido-α-D-galactopyranosyl)-2-(N-nervonoylamino)-1,3,4-octadecanetriol 
• 1224436-76-3 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-diol 
• 1262283-53-3 C₃₉H₆₃NO₆SSi 
• 1262283-52-2 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-cyclic sulfate 
• 1262283-54-4 (4S,5R)-4-((tert-butyldiphenylsilyloxy)methyl)-5-((R)-1-hydroxypentadecyl)oxazolidin-2-one 
• 1262283-55-5 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-5-hydroxy-6-tetradecyl-1,3-oxazinan-2-one 
• 1262283-59-9 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-diol dimethanesulfonate 
• 1262283-61-3 (R)-1-((4S,5R)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxooxazolidin-5-yl)pentadecyl methanesulfonate 
• 1262283-60-2 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxo-6-tetradecyl-1,3-oxazinan-5-yl methanesulfonate 
• 1262283-63-5 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxo-6-tetradecyl-1,3-oxazinan-5-yl trifluoromethanesulfonate 

Relevant articles and documents

A practical and scalable synthesis of KRN7000 using glycosyl iodide as the glycosyl donor

KRN7000 is particularly useful because it is a powerful and specific CD1d agonist and has prompted intense interest in the context of immunology in the past 25 years. Its limited commercial availability and high price has led to the publication of many different syntheses. However, almost all of them focused on the methodology development rather than a scalable synthesis. Herein, we have described a practical and scalable procedure for the synthesis of KRN7000 basing on the glycosyl iodide method. This procedure involves total of eight steps to obtain the highly pure product KNR7000 on gram scale from the commercially available starting materials (d-galactose and the phytosphingosine) with only three column chromatographic purifications.

4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.